Publications by authors named "Leonel Gallegos"
Epigenetic therapeutics such as the histone deacetylase inhibitor, vorinostat, and the DNA methyltransferase I inhibitor, azacitidine, enhance gemtuzumab ozogamicin efficacy in vitro. We therefore investigated vorinostat/azacitidine/gemtuzumab ozogamicin in 52 adults aged 50 years or over with acute myeloid leukemia requiring therapy for first relapse (remission duration ≤ 12 months) or primary refractory disease in a phase I/II trial. Vorinostat and gemtuzumab ozogamicin were escalated step-wise during the phase I portion of the trial.
View Article and Find Full Text PDFArticle Synopsis
- Limited treatment options for older patients with acute myeloid leukemia (AML) prompt the exploration of new therapies, with azacitidine combined with lenalidomide being evaluated as a front-line treatment.
- In a study involving 42 patients aged 60 and older, the treatment showed an overall response rate of 40%, with complete remission occurring in 28% of cases, and a median time to remission of 12 weeks.
- While severe side effects were rare, 17% of patients experienced early death, highlighting the need for ongoing research into the efficacy and safety of this treatment combination.